Fig. 3 | Scientific Reports

Fig. 3

From: A phase 1b randomised clinical trial evaluating BBI-001, a non-absorbed oral therapeutic for the treatment of iron overload

Fig. 3

BBI-001 reduces iron isotope absorption. (A) BBI-001 significantly reduced iron absorption for all subjects compared to placebo (PBO), p < 0.05 (p = 0.018). (B) For individuals hyperabsorbing iron (> 3 mg iron absorbed on PBO), BBI-001 reduction of iron absorption was significant, p < 0.01 (p = 0.0023). Statistical analysis used a paired, two-tailed, t-test. Insets: Iron absorption per subject, placebo versus BBI-001 and mean change in iron absorbed.

Back to article page